How do you operationally distinguish MASLD from MetALD in patients with obesity/diabetes and possible hazardous drinking when objective alcohol biomarkers (e.g., PEth) are unavailable, in a way that actually changes management priorities (e.g., focus of therapy and timing of transplant referral)?